Ọgwụ Lipantil: ntuziaka maka ojiji

na pịpị 10 mebiri emebi., n'ime mkpọ nke kaadiboodu 3 blisters.

Mlọ ọgwụ

Lowers triglycerides na, ruo obere obere, cholesterol n'ime ọbara. Ọ na - enyere aka belata ọdịnaya nke VLDL, ruo ntakịrị - LDL, mụbaa ọdịnaya nke anti-atherogenic HDL. Ọ na - eme ka lipoprotein lipase na, yabụ, na - emetụta metabolism nke triglycerides, na - akụghasị njikọ nke abụba abụba na cholesterol, ma na - enyere aka ịbawanye ọnụ ọgụgụ ndị na - anabata LDL na imeju. Fenofibrate na-ebelata nchịkọta platelet, belata ọkwa fibrinogen dị elu nke plasma, nwere ike belata ọkwa glucose ọbara na ndị ọrịa nwere ọrịa mellitus, wee belata ọkwa uric acid na ọbara.

Mlọ ọgwụ

Ihe bụ isi metabolite bụ fenofibroic acid. Mgbe ị takingụsịrị ọgwụ ahụ n’ime C_max na plasma ruru mgbe awa 5. Mgbe ewere ya na 200 mg, nkezi mkpụrụ plasma bụ 15 isg / ml. Ọgwụ plasma nke ọgwụ a kwụsiri ike. Ndi_1/2 fenofibroic acid - ihe dị ka awa 20. Ọ na - abụkarị ya na mmamịrị (fenofibroic acid na glucuronide) mgbe ụbọchị isii gachara. Ọ naghị ekpokọ mgbe ị na-a aụ otu ọgwụ were ogologo oge. A na - apụtakarị Fenofibroic acid n'oge usoro ịba ọcha n'anya.

Ihe ngbanwe

Ọrịa gabigara oke arụ na akụrụ, akụkọ ihe mere eme nke fototoxic ma ọ bụ mmeghachi omume photoallergic n'oge ọgwụgwọ na fenofibrates ma ọ bụ ọgwụ ndị ọzọ yiri ya na ihe owuwu, ọkachasị ketoprofen, njikọta na fibrates ndị ọzọ, ụmụaka na-erubeghị afọ 18, afọ ime, lactation, congenital galactosemia, ụkọ lactase.

Nsonaazụ

Di iche iche na myalgia, ahuhu akwara, adighi ike, na (na mgbe ufodu) rhabdomyolysis, ufodu siri ike. Mgbe a kwụsịrị ọgwụgwọ, ihe omume ndị a na-agbanwe agbanwe.

Site na eriri afọ: dyspepsia. Activityba ụba nke ọrụ ịba ọcha n'anya na ọbara.

Mmeghachi omume nfụkasị ahụ: ọnya anụ - shehes, urticaria, photoensitivity. N'ọnọdụ ụfọdụ (mgbe ọnwa ole ijiri were mee), mmeghachi omume na-ahụ maka eserese nwere ike ịmalite n'ụdị erythema, papules, vesicles, ma ọ bụ eczematous rashes.

Mmekorita

Njikọ ọnụ nke a na - ekwekọrịta: fi na - eme ihe ndị ọzọ.

Ationsgwakọta ndị a na-achọghị: ya na ndị na - egbochi HMG-CoA reductase - ihe dị oke nfe nke nsonazụ (mmebi akwara).

Ejikọtara ọnụ iji kpachara anya - na anticoagulants na-apụtachaghị ìhè (ihe ize ndụ nke ọbara ọgbụgba). Njikwa PV ugboro ugboro dị mkpa mgbe a na-ahọrọ ọgwụ anticoagulant na-apụtaghị ìhè n'oge ọgwụgwọ fibrates na n'ime ụbọchị 8 mgbe mmịpụ ha gasịrị.

A naghị eji Fenofibrate emekọ ihe ọnụ na MAO inhibitors.

Nchedo nchekwa

Enwere akụkọ banyere nsị fibrates n'ahụ anụ ahụ, gụnyere obere ikpe nke necrosis. Usoro ndị a na - abụkarị nke na - ebute plasma albumin dị ala. Ekwesịrị ichebara mmetụta ahụ egosipụtara na ndị ọrịa niile na-agbasa myalgia, na mwepụ akwara ma nwee mmụba dị ukwuu na ọkwa nke creatine phosphokinase (5 ugboro karịa nke nkịtị). N'ụdị ndị a, ekwesịrị ịkwụsị usoro ọgwụgwọ.

Na mgbakwunye, enwere ike imebi akwara ma ọ bụrụ na etinyere ọgwụ mgbochi HMG-CoA reductase inhibitors.

N'ihi ọnụnọ nke lactose, ọgwụ a machibidoro ọrịa ụyọkọ galactosemia, ma ọ bụrụ na ọrịa glucose na galactose malabsorption ma ọ bụ nke ụkọ lactase.

Ọ bụrụ na enwetabeghị afọ ojuju na ọgwụ ọnụnọ enwetara n'oge iji ọgwụ ahụ maka ọnwa 3-6, ekwesịrị inye usoro ọgwụgwọ ọzọ.

Inyocha usoro nke hepatic transaminases n'ime ọbara n'ọbara n'ime ọnwa atọ ọ bụla n'ime ọnwa 12 mbụ ọgwụgwọ dị mkpa. Ọ bụrụ na ọkwa nke AST na ALT mụbara karịa ugboro atọ ma e jiri ya tụnyere VGN, ekwesịrị ịkwụsị usoro ọgwụgwọ.

Mgbe ejikọtara na anticoagulants na-apụtaghị ìhè, ọ dị mkpa iji nlezianya nyochaa usoro coagulation ọbara dị mkpa.

Omume ọgwụ

Onye na-ahụ maka hypolipPs, nwere mmetụta uricosuric na antiplatelet. Na-ebelata cholesterol ọbara n'ogo site na 20-25%, TG ọbara site na 40-45% na uricemia site na 25%. Site na usoro ọgwụgwọ dị ogologo oge, a na-ebelata nkwụnye cholesterol extravascular.

Na-ebelata mkpokọta nke TG, VLDL, LDL (ruo obere obere), na-abawanye - HDL, na-akụghasị njikọ nke ọdụdụ abụba. Na-ebelata nchịkọta platelet, belata ọdịnaya plasma fibrinogen dị elu. N'ime ndị ọrịa nwere ọrịa shuga nwere ụfọdụ mmetụta hypoglycemic.

Ntụziaka pụrụ iche

Ekwesịrị ịmalite ọgwụgwọ yana nri cholesterol na nlekọta nke dọkịta.

Ọ bụrụ na enweghị mmetụta na-eju afọ mgbe ọnwa 3-6 nke nchịkwa gasịrị, enwere ike ịkọwa akara nkwekọrịta ma ọ bụ usoro ọgwụgwọ ọzọ.

Ọ na-atụ aro ka nyochaa ọrụ “transperent hepatic” kwa ọnwa atọ n’ime afọ mbụ nke ọgwụgwọ, nkwụsịtụ nwa oge na ọgwụgwọ ma ọ bụrụ na ọrụ ha na-aba ụba, na mwepu ya n’otu oge nke ọgwụ hepatotoxic.

Ngwakọta na usoro onunu ogwu

Ọgwụ Lipantil 200 m bụ nke otu ọgwụ ọgwụ ngwaahịa fibroic acid. Ihe bụ isi na - arụ ọrụ bụ fenofibrate. Ọ na - eme ihe na ndị na - anabata PPA-α, na - eme ka usoro nke lipoprotein lipase rụọ ọrụ. Usoro a na - eme ka ịba abụba ma wepụ irighiri ihe na - egbochi ọbara. Ya mere, ogo nke lipoproteins dị ntakịrị na-agbadata otu, na ọnụọgụ nke lipoproteins dị elu, n'ụzọ megidere, na-abawanye. Fibrate na-apụkwa n'ụzọ ọzọ na-ebelata shuga ọbara. Ọgwụ na - enyere aka ịhazi fibrinogen, na - egbochi ịmịkọ ọbara.

Releasedị mgbapụta nke Lipantil bụ capsule siri ike nke brownlatul gelatin nwere ntụ ọcha n'ime. Ọgwụ dị na usoro nke 200 mg, iberibe 30 kwa mkpọ. Obodo amụrụ - France. Nwere ike ịzụta ọgwụ naanị site na ndenye ọgwụ.

Ihe ngosi maka ojiji

Cholesterol dị elu nke ogo nke abụọ na nke abụọ dị ka Fredrickson si bụrụ ihe pụtara ìhè maka nhọpụta Lipantil. Site na hyperlipidemia jikọtara ọnụ, a na-atụ aro ịgụnye mbadamba Lipantil na atụmatụ ọgwụgwọ. Nnukwu triglycerides chọkwara fenofibrate. Ọrịa atherosclerosis na-aga n'ihu na-eme ka ohere nke ịrịa ọrịa myocardial na ọrịa strok dị. N'akụkụ a, maka mgbochi, ndị dọkịta na-atụ aro Lipantil.

Site na ntachi obi na ọgwụ hypoliplera ndị ọzọ, dịka ọmụmaatụ, akpụ akpụ, iji fenofibrate dịka ihe ọzọ egosipụtara.

Nsonaazụ

Ọtụtụ mgbe, ndị ọrịa na-eme mkpesa maka nsogbu nri. Mgbe ụfọdụ mgbu mgbu nwere ike ime, n'ọnọdụ kachasị njọ, mbibi nke akwara anụ ahụ. A na-ahụkwa mmeghachi omume hypers na akụkụ nke Lipantil. Ntupu na itching nwere ike iputa. Dịka ọtụtụ ọgwụ ọgwụ na-egbusi ike, fenofibrate na-abawanye ọkwa nke enzymes imeju na ọbara. Ka ngwụcha usoro ọgwụgwọ ahụ gasịrị, mmetụta ọ na-eso na-apụ n'anya na-enweghị ọnaghị ọnyà.

N'ọnọdụ ndị ị rareụbiga ọseụ overụ ókè, a na-eme ọgwụgwọ Symptomatic.

Usoro onunu ogwu na nhazi

Na ezigbo dọkịta gị nwere ike ịhọrọ gị, were n'uche akụkọ gbasara ahụike gị. Usoro onunu ogwu bu 200 mg nke ogwu ubochi. Na uche nke dọkịta, mgbe ụfọdụ enwere ike kee ubochi ọ bụla ụbọchị ụzọ atọ. A na-ewere okpu ahụ na nri, were mmiri sachaa ya. N'ime ọrịa dị egwu, ịchọrọ ị needụ ọgwụ kwa ụbọchị nwere ike iru 400 mg. N'okwu a, onye ọrịa nọ na-eche nche nke ndị ọrụ ahụike.

Njirimara ngwa

Ejila ọgwụ eji eme ihe maka malabsorption nke glucose, galactose. Mgbe ị na-edepụta usoro dị iche iche nke fibroic acid, ọ dị mkpa iji hazie usoro nyocha nke imeju. A na-enyocha ihe ndị na-eme ka ọbara na-arụ ọrụ nke ọma. Na agbanyeghị enweghị ike ịme fibrates na mmanya. Njikọ dị otú ahụ nwere ike ịnwe nsí dị oke egwu na mkpụrụ ndụ imeju, n'ọnọdụ kachasị njọ, yana nsonaazụ na-enweghị atụ.

N'oge ime na lactation

Oge ịtụrụ ime ga - ewepụ ọgwụ ọgwụ. N'ezie, dịka ị na-enye nwa ara. Ebe ọ bụ na site na mmiri ara, ọgwụ nwere ike imetụta nwa ọhụrụ ahụ.

Enweghị data nyocha banyere nsonaazụ ọgwụ dị n'ahụ ahụ ụmụaka. Na nke a, ọ na-contraindicated na ụmụ.

Ọnụ ahịa ọgwụ ọjọọ

Fenofibrate, aha ahia Lipantil 200 M, enwere ike zụta na Ukraine na ọnụahịa ruru 520 UAH maka mbadamba 30. N'ime ụlọ ahịa ọgwụ nke Russian Federation, ọgwụ ga-efu gị nkezi 920 rubles maka ngwugwu yiri ya. Echefula igosi onye na-ere ọgwụ gị ọgwụ n’aka dọkịta tupu ịzụta. Gbalia lelee ma ogwu gi emebiela.

Analogs Lipantil

Ọ bụrụ na usoro onunu ogwu nke Lipantil dị oke karịa onye ọrịa, a ga-eji dochie ọdịnaya nwere obere ahụ. Dịka ọmụmaatụ, Tricor, nke a na -emepụta ntụtụ nke 145 mg na otu mbadamba osisi n'otu Lipantil. Ndị ọzọ mmekorita ego na-etinye ego gụnyere Fenofibrat Canon, nke Russia mere, na Exlip, Turkey. Naanị dọkịta gị ga - enyere aka mechaa ghọta ọtụtụ ihe ndị na - eme ọgwụ na - emegide cholesterol. Ekwela ka naanị ozi sitere na ịntanetị.

Nyocha Nyocha

Nkwupụta nke ndị dọkịta kwuru gbasara ọgwụ ọgwụ doro anya - ọ nwere mmetụta dị mma dị. N'ime ọnwa mbụ nke ọgwụgwọ, ọ ga-ekwe omume ịtụle nsonaazụ mbụ yana, ọ bụrụ na ọ dị mkpa, dozie dose ahụ. Enwere ike iji Lipantil mee ihe dị ka monotherapy, ma ọ bụ na njikọta ọgwụ ndị ọzọ.

Ndị ọrịa na-echegbu onwe ha karịa mmetụta ọgwụ ọjọọ dị na imeju. Ma mbelata nke cholesterol zuru oke na-akwụghachi ụgwọ ọnụnọ nke nsonaazụ ya. Ọtụtụ ndị mmadụ mara na enwere ike ịchịkwa ma kwụsị mmetụta ọjọọ nke ị pụ ọgwụ. Ma n'eziokwu, ọnụahịa ahụ anaghị adabara onye ọ bụla. Agbanyeghị, ọtụtụ kwenyere na ngwaahịa dị mma na nke nwere ikikere ruru ego ahụ.

Mpempe usoro onunu ogwu

Otu Capsule nwere

ihe na - arụ ọrụ - micronized fenofibrate 200 mg,

ndị na-ebu ụzọ: lactose, sodium lauryl sulfate, sitara pregelatinized, crospovidone, magnesium stearate,

shei ahihia: titanium dioxide (E 171), Iron (III) ọla edo edo E172, Iron (III) oxide uhie E172, gelatin.

Opaque capsules light brown brown 1. Ihe dị na capsules na-acha ọcha ma ọ bụ ihe fọrọ nke nta ka ọ bụrụ ntụ ntụ

Doụbiga ọgwụ ike ókè na ị drugụ ọgwụ

N'ime omume ụlọọgwụ, ụdị ọrịa a na - adịkarị ụkọ. Dodoụbiga ihe ọ ofụ overụ nke Lipantil bụ nke ụra na-egosipụta site na iro ụra, ọgba aghara, ọgbụgbọ, iwe. A chọrọ akwa Gastric, yana ị nweta enterosorbent ọ bụla - carbon na-arụ ọrụ, Smecta, Enterosgel. Ọ dị mkpa ịchọrọ enyemaka ahụike ozugbo maka ịpụpụ na ọgwụgwọ ọrịa Symptomatic.

A na - eme ka mmetụta hypoglycemic nke ọgwụ nwere ihe dị n'ụkpụrụ sulfonylurea na iji otu oge ha na Lipantil. Ọ na - eme ka nrụpụta ọgwụgwọ nke coagulants na - apụtaghị ìhè, nke anaghị adị mma mgbe niile. Njikọ nke cyclosporine na olu nwere ike ịmịlata mbelata nke ọrụ akụkụ akwara, ọkachasị akụrụ.

Njikọ aka na usoro ọgwụgwọ Lipantil na ọgwụ ọ bụla sitere na statin otu ga-ekwe omume naanị ma ọ bụrụ na onye ọrịa ahụ nwere nnukwu ọrịa dyslipidemia nwere nnukwu ọrịa obi, na enweghị akụkọ banyere akwara ọrịa. A na-eme ọgwụgwọ ọgwụgwọ n'ọnọdụ nlezianya nlekọta ahụike iji chọpụta njirimara nke ihe mmerụ ahụ na-emebi akwara ọkpụkpụ.

Analogs na ọnụahịa

Cardiologists de Lipantil analogues na anabataghi ya na ihe ya n’eme. A na-ejikwa mmegharị arụ ọrụ na arụmọrụ dị ala nke iji ya ruo ọtụtụ ọnwa, mbelata nke ogo triglycerides yana obere lipoproteins dị ala.

Omume ị usingụ ọgwụ ike nwere oke igbari cholesterol ma wepu ha n'ahụ. N'ime usoro analogues nke Lipantil, Fenofibrate na-agbakarị akwụkwọ. Clofibrate na gemfibrozil nwere ọrụ ọgwụgwọ ahụ yiri ya.

Ọnụ ahịa Lipantil dịgasị iche na mpaghara dị iche iche nke mba ahụ. Na Moscow, enwere ike ịzụta ngwugwu nke mbadamba No. 30 na dose nke 200 mg maka 780 rubles. Na Nizhny Novgorod ọ na-efu 800 rubles, na Volgograd ọnụ ahịa ya bụ 820 rubles.

Ikpebi nhọrọ nke ọgwụ dị mma ma dị elu iji belata ọkwa triglycerides na oke ọbara bụ ihe dị mfe. Na saịtị ahụike na ọgwụ, enwere ọtụtụ nyocha dị mma banyere Lipantil. Ndị ọrịa Cardiologist na-ekwu na ọgwụ ahụ na-ewepụ ihe ịrịba ama niile nke hyperlipidemia n'ime ọnwa 2-3. Ha na-ekwusi ike na nchekwa ọgwụ, ngosipụta dị ụkọ nke nsonaazụ mpaghara yana usoro.

Maria Dmitrievna, onye gbara afọ 64, Ryazan: ọkwa cholesterol m bilitere site na afọ 50. Na mbido, enweghị mgbaàmà ọ bụla, mana ahụike ya kawanyere njọ. Isi m malitere inwe nkụda mmụọ, mkpụmkpụ nke iku ume pụtara na obere ije. Ọkpụkpụ akwara ahụ tụrụ aro iwere ọgwụ Lipantil ọnwa atọ. Ahụike malitere ịdị mma n'ihe dịka otu ọnwa.

Nikolay, onye gbara afọ 49, Zheleznovodsk: Enwere m ihe ga - egbochi ihe ga-eme n'ọrịa obi. Ya mere, kadiologist deere usoro ọgwụgwọ ozugbo ọ mechara chọpụta ọkwa dị elu nke triglycerides. Na mbu, m were ọgwụ sitere na statin otu, mana nsonaazụ ya ka njọ karịa ka a tụrụ anya. Dọkịta tụrụ aro ị Liụ Lipantil na ọgwụ nke 200 mg. Ọnwa atọ ka e mesịrị, data kemịkalị dị mma nke ukwuu.

Ngwongwo ogwu

Egwu. Mgbe nchịkwa ọnụ nke Lipantil 200M Cmax capsule (ịta kachasị), a na-enweta fenofibroic acid mgbe awa 4-5. Site n'iji ogologo oge, ntinye fenofibroic acid na plasma na-adịgide, n'agbanyeghị ụdị njiri mara onye ọrịa. Cmax na plasma ọbara na mmetụta n'ozuzu fnofibrate micronized na-abawanye na nri oriri.

Fenofibroic acid siri ike na ihe karịrị 99% dị na plasma albumin.

Metabolism na ntụpọ

Mgbe nchịkwa ọnụ gasịrị, mmiri ọgwụ fenofibrate na-agbaze mmiri ngwa ngwa site na esterases na fenofibroic acid, nke bụ metabolite ya bụ isi. Achọpụtaghị Fenofibrate na plasma. Fenofibrate abụghị mkpụrụ maka CYP3A4, anaghị etinye aka na metabolismal metabolism na imeju.

Fenofibrate bụ nke dịkarịrị na mmamịrị n'ụdị fenofibroic acid na glucuronide conjugate. N'ime ụbọchị isii, a na-ewepụ fenofibrate kpamkpam. N'ime ndị ọrịa agadi, mkpochapu fenofibroic acid anaghị agbanwe. Ndụ ọkara nke fenofibroic acid (T1 / 2) bụ ihe dị ka awa 20. Mgbe egosighi hemodialysis. Nnyocha ndị e mere na kinetic egosiwo na fenofibrate anaghị achịkọ ma otu ogologo oge were ya ogologo oge.

Onye na - ahụ maka hypolipPs sitere na njirisi nke fibroic acid.Fenofibrate nwere ikike ịgbanwe ihe dị n'ime ahụ mmadụ site na mmụba nke ndị na - anabata ndị na - anabata PPAR-((ndị na - eme ihe alfa nke ndị na - eme mkpọtụ peroxisome).

Fenofibrate na-eme ka lipolysis nke plasma na mwepụ nke atherogenic lipoproteins nwee nnukwu ọdịnaya nke triglycerides site na ịgbalite ndị na-anabata PPAR-α, lipoprotein lipase ma belata njikọta nke apoprotein C-III (apo C-III). Mmetụta ndị akọwapụtara n’elu na-eduga na mbelata nke lipoprotein dị ntakịrị (LDL) yana obere lipoprotein dị ala (VLDL), nke gụnyere apoprotein B (apo B), na mmụba nke akụkụ nke lipoprotein dị elu (HDL), nke gụnyere apoprotein A-I ( apo A-I) na apoprotein A-II (apo A-II). Na mgbakwunye, n'ihi mgbazi nke njikọta na ọrịa catabolism nke VLDL, fenofibrate na-eme ka mmụpụ nke LDL belata ma belata ọdịnaya nke obere LDL (mmụba na LDL ndị a nwere ndị ọrịa nwere mkpụrụ ndụ atherogenic lipid phenotype ma jikọtara ya na nnukwu ihe ize ndụ nke ọrịa obi na-arịa obi-IHD).

N'ime ọmụmụ ụlọ ọgwụ, achọpụtara na iji fenofibrate belata ọkwa nke cholesterol ngụkọta (Ch) site na 20-25% na triglycerides site na 40-55% na mmụba nke ọkwa HDL-C site na 10-30%. N’ime ndị ọrịa nwere hypercholesterolemia, ebe eji ewelata ọkwa Chs-LDL site na 20-35%, ojiji nke fenofibrate butere mbelata nke oke: mkpokọta Chs / Chs-HDL, Chs-LDL / Chs-HDL na apo B / apo A-I, nke bụ ihe nrịbama nke atherogenic ihe egwu.

N'ịtụle nsonaazụ fenofibrate na ọkwa nke LDL-C na triglycerides, ojiji nke ọgwụ ahụ dị irè na ndị ọrịa nwere hypercholesterolemia, ha na hypertriglyceridemia na - esoghị, gụnyere hyperlipoproteinemia nke abụọ, dịka ọmụmaatụ, na ụdị ọrịa shuga 2 mellitus.

Enwere ihe akaebe na fibrates nwere ike belata ọrịa obi obi, mana ọnweghị ihe akaebe na-ebelata ọnwụ na mkpokọta mgbochi ma ọ bụ nke abụọ nke ọrịa obi.

N'oge ọgwụgwọ fenofibrate, nkwụnye ego nke XC (akwara na xanthomas) nwere ike belata nke ukwuu ma kwụsị kpamkpam. N'ime ndị ọrịa nwere ọkwa fibrinogen dị elu nke natara ọgwụgwọ fenofibrate, a chọpụtara mbelata dị ukwuu na ihe ngosi a, yana ndị ọrịa nwere ọkwa lipoprotein dị elu. Na usoro ọgwụgwọ fenofibrate, a na-achọpụta mbelata nke protein C-reactive na ihe nrịbama ndị ọzọ nke ọrịa.

Maka ndị ọrịa nwere ọrịa dyslipidemia na hyperuricemia, uru ọzọ bụ na fenofibrate nwere mmetụta uricosuric, nke na-eduga n'ịbelata uric acid n'ihe dị ka 25%.

N'ime ọmụmụ ụlọ ọgwụ na nyocha anụmanụ, egosipụtara fenofibrate iji belata nchịkọta platelet nke adenosine diphosphate, arachidonic acid, na epinephrine.

Mkparịta ụka ọgwụ ọjọọ

A naghị akwado ọgwụ anticoagulants n'otu oge ahụ dị ka Lipantil 200M. Fenofibrate na-akwalite mmetụta nke ọgwụ anticoagulants na-akpata ma nwee ike ịbawanye ohere nke ọbara ọgbụgba. Na mmalite ọgwụgwọ fenofibrate, a na-atụ aro ka ọ belata ọgwụ anticoagulants ihe dị ka otu ụzọ n'ụzọ atọ, na-esote usoro iji nwayọ nwayọ. A na-atụ aro ịhọrọ dose ka ọ rụọ ọrụ n'okpuru njikwa nke ọkwa MHO (oke ijikọ mba ụwa).

Cyclosporin. A kọwo ọtụtụ ikpe siri ike nke ịlaghachi n'ọrụ akụrụngwa n'oge ọgwụgwọ n'otu oge na fenofibrate na cyclosporine. Yabụ, ọ dị mkpa inyocha ọnọdụ ọrụ gbasara akụrụngwa na ndị ọrịa dị otú a ma kagbuo Lipantil 200M ma ọ bụrụ na nnukwu mgbanwe na plọg ụlọ nyocha.

Ngalaba mgbochi mbelata ihe ndị na - egbochi ndị ọzọ. Mgbe ị na-ewere fenofibrate n'otu oge ahụ HMG-CoA reductase inhibitors ma ọ bụ fibrates ndị ọzọ, a na-abawanye ihe ọghọm nke nsonaazụ nsị na akwara ike. Ọ dị mkpa iji ọgwụ ọjọọ nke otu a na Lipantil 200M jiri nlezianya mee ihe, ndị ọrịa chọrọ nlezianya maka ihe ịrịba ama nke nsí muscle.

Glitazones. Enwere akụkọ banyere mgbanwe dị mma na-agbanwe agbanwe na HDL cholesterol ka ị na-ewere fenofibrate yana ọgwụ sitere na glitazone. Ya mere, a na-atụ aro ka ị nyochaa ọkwa nke HDL cholesterol na ojiji ọgwụ jikọtara ọnụ ma ọ bụ nkwụsị nke otu n'ime ha, yana oke ọkwa HDL cholesterol.

Enzymes Cytochrome P450. Na nyocha nke vitro nke microsomes mmadụ gosipụtara na fenofibrate na fenofibroic acid abụghị ndị na-egbochi isoenzymes CYP3A4, CYP2D6, CYP2E1 ma ọ bụ CYP1A2. Na mpaghara ọgwụgwọ, ogige ndị a bụ ndị na - egbochi CYP2C19 na CYP2A6 isoenzymes na ndị na - adịghị ike ma ọ bụ ndị na - egbochi CYP2C9.

Ndị ọrịa na-a drugsụ ọgwụ nwere obere ọgwụgwọ ọgwụgwọ n'otu oge na fenofibrate, na metabolism nke enzymes CYP2C19, CYP2A6 na, ọkachasị, CYP2C9 na-etinye aka, chọrọ nlezianya nlezianya. Ọ bụrụ na ọ dị mkpa, a na-atụ aro ịmegharị ọgwụ ụfọdụ.